1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Stentys
  6. News
  7. Summary
    STNT   FR0010949404

STENTYS

(STNT)
End-of-day quote Euronext Paris  -  07-21
0.4600 EUR   -2.95%
2020Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020STENTYS : Financial Information for the First Quarter Of 2020
BU
2020STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020
CI
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Stentys : Financial Information for the First Quarter of 2020

05/15/2020 | 08:40am EDT

Financial Information for the First Quarter of 2020

  • Q1 2020 consolidated revenues of €0.8 million
  • Liquidation of the Group's inventories
  • Consolidated cash position of €6.1 million at March 31, 2020

PARIS - May 15, 2020 - 5.45 pm CEST - STENTYS (FR0010949404 - STNT), a French group specialized in medical technologies for interventional cardiology, today reported its consolidated quarterly revenues and cash position at March 31, 2020.

First-quarter revenues by geographical region

€ thousands

Q1 2020

Q1 2019

% change

Europe1

442

1,357

-67%

Rest of the world

315

1,243

-75%

Total revenues

757

2,600

-71%

Audited data

First-quarter revenues by product category

€ thousands

Q1 2020

Q1 2019

% change

Stents

133

1,638

-92%

Balloons & accessories

624

961

-35%

Total revenues

757

2,600

-71%

Audited data

During the first quarter of 2020, the Company liquidated its inventories. On the date of publication of this press release, the Company no longer has regulatory clearance to market its products. Unsold products have been destroyed. STENTYS will henceforth generate no further revenues.

Cash position of €6.1 million

The Group had a cash position of €6.1 million at March 31, 2020 versus €8.2 million at December 31, 2019.

Additional information is available at www.stentys.com.

1 Germany, Italy, Switzerland, Austria, Poland, Netherlands, France, Belgium, United Kingdom, Spain, Greece, Portugal and Nordic countries.

Page 1 of 2

STENTYS

NewCap

André Lerebours

Investor Relations / Strategic Communications

CFO

Dusan Oresansky / Pierre Laurent

Tel.: +33 (0)1 44 53 99 42

Tel.: +33 (0)1 44 71 94 92

investor@stentys.com

stentys@newcap.eu

STENTYS is listed on Compartment C of Euronext Paris

ISIN: FR0010949404 - Ticker: STNT

***

Forward-looking statements

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company's products, market acceptance of the Company's products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 "Risk Factors" of the Company's 2016 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers (AMF) on November 29, 2017 under number D.17-1084.

Page 2 sur 2

Disclaimer

Stentys SA published this content on 15 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 May 2020 12:39:01 UTC


© Publicnow 2020
All news about STENTYS
2020Stentys S.A. Reports Earnings Results for the Half Year Ended June 30, 2020
CI
2020STENTYS : Financial Information for the First Quarter Of 2020
BU
2020STENTYS S.A. Announces Revenue Results for the First Quarter Of 2020
CI
2020STENTYS : Financial Information for the First Quarter of 2020
PU
2020STENTYS : 1st quarter earnings
CO
2020STENTYS : 2019 Annual Results
PU
2020STENTYS : Annual results
CO
2019STENTYS : Convening of another Combined General Meeting on November 14, 2019
PU
2019STENTYS : 2019 half-year results
PU
2019Stentys Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2019
CI
More news
Chart STENTYS
Duration : Period :
Stentys Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
Michel Darnaud Chairman & Chief Executive Officer
André Lerebours Chief Financial Officer & Deputy CEO
Marie Meynadier Independent Director
Sophie Baratte Independent Director
Christian M. Spaulding Independent Director
Sector and Competitors
1st jan.Capi. (M$)
STENTYS0.00%17
ABBOTT LABORATORIES-18.27%201 411
MEDTRONIC PLC0.78%139 869
BECTON, DICKINSON AND COMPANY4.57%73 262
HOYA CORPORATION-21.65%38 307
BAXTER INTERNATIONAL INC.-14.53%36 944